LPL Financial LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 751,945 shares of the medical research company's stock after purchasing an additional 4,999 shares during the period. LPL Financial LLC owned approximately 0.14% of Amgen worth $242,284,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of AMGN. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the third quarter worth about $25,000. Strategic Financial Concepts LLC acquired a new position in Amgen in the second quarter worth $26,000. Hershey Financial Advisers LLC bought a new position in shares of Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC acquired a new stake in Amgen in the second quarter worth $31,000. Finally, Bbjs Financial Advisors LLC bought a new position in Amgen in the 2nd quarter worth about $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Stock Up 0.8 %
Shares of AMGN traded up $2.41 during trading hours on Friday, reaching $292.31. 485,084 shares of the stock traded hands, compared to its average volume of 2,466,125. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market cap of $157.13 billion, a price-to-earnings ratio of 37.10, a PEG ratio of 2.50 and a beta of 0.60. Amgen Inc. has a 52 week low of $260.68 and a 52 week high of $346.85. The stock has a fifty day simple moving average of $317.28 and a 200 day simple moving average of $318.02.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm's revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the firm posted $4.96 EPS. On average, equities analysts forecast that Amgen Inc. will post 19.51 EPS for the current year.
Amgen Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.08%. The ex-dividend date of this dividend is Monday, November 18th. Amgen's dividend payout ratio (DPR) is 115.24%.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. TD Cowen boosted their price target on shares of Amgen from $381.00 to $383.00 and gave the company a "buy" rating in a report on Monday, October 21st. Robert W. Baird restated an "underperform" rating and issued a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. Citigroup initiated coverage on shares of Amgen in a research note on Thursday, November 14th. They issued a "neutral" rating and a $335.00 target price for the company. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $333.57.
Get Our Latest Analysis on AMGN
Amgen Company Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
